← Back to all trials
Not Yet Recruiting
NCT05718791
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Conditions: GVHD,Acute
Sex: All
Ages: 18 Years – 80 Years
Enrollment: 100
Sponsor: Henry Ford Health System
Location: United States
Summary
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT.
The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Eligibility Criteria
Inclusion Criteria:Patients >18 year old admitted for allo SCT PB for malignant disease.
Source: ClinicalTrials.gov (NCT05718791). StuddyBuddy aggregates publicly available trial information.
